A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma

Biotechnology Annual Review

Volumn 11, Issue SUPPL., 2005, Pages 381-389

  Sawka, Carol Anne ^a,b   Shepherd, Frances A ^b,c   Franssen, Edmee ^a,b   Brandwein, Joseph ^b,c   Dotten, Dale A ^b   Routy, Jean Pierre G ^d   Walker, Irwin R ^e   St Louis, Jean ^f   Taylor, Marianne ^g   Arts, Karen ^h   Crump, Michael ^b,c   Foote, Mary Ann ⁱ  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e HAMILTON HEALTH SCIENCES   (Canada)

^f MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h Amgen Canada Inc   (Canada)

ⁱ AMGEN INC   (United States)

Author keywords

Acquired immunodeficiency syndrome; Chemotherapy trials; Clinical survival; Highly active antiretroviral therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ALOPECIA; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; FILGRASTIM; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

PNEUMOCYSTIS CARINII;

EID: 27144473383     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(05)11012-6     Document Type: Review

References (14)

1. Stebbing J Marvin V and Bower M The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma Cancer Treat Rev 30 2004 249-253
2. Mitsuyasu R Oncological complications of human immunodeficiency virus disease and hematologic consequences of their treatment Clin Infect Dis 29 1999 35-43
3. Goedert JJ Cote TR Virgo P Scappa SM Kingma DW Gail MH Jaffe ES and Biggar RJ the AIDS-Cancer Match Study Group Spectrum of AIDS-related Kaposi's sarcoma Lancet 351 1998 1833-1839
4. Chiu BC and Weisenburger DD An update of the epidemiology of non-Hodgkin's lymphoma Clin Lymphoma 4 2003 161-168
5. Sawka CA Shepherd FA Brandwein J Burkes RL Sutton DM and Warner E Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program Leuk Lymphoma 8 1992 213-220
6. Anonymous A predictive model for aggressive non-Hodgkin's lymphoma. International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med 329 1993 987-994
7. Kaplan EL and Meier P Nonparametric estimation from incomplete observations Am Stat Assoc J 53 1958 457-481
8. Miller V Mocroft A and Reiss P et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study Ann Intern Med 130 1999 570-577
9. Besson C Goubar A Gabarre J Rozenbaum U Pialoux G Clatelet FP Katlama C Charlotte F Dupont B Brousse N Huerre M Mikol J Camparo P Mokhtari K Tulliez M Salmon-Ceron D Boue F Costagliola D and Raphael M Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy Blood 98 2001 2339-2344
10. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. JNCI 2000;92: 1823-1830
11. Levine AM Seneviratne L and Espina BM et al. Evolving characteristics of AIDS-related lymphoma Blood 96 2000 4084-4090
12. Kaplan LD Straus DJ Testa MA Von Roenn J Dezube BJ Cooley TP Herndier B Northfelt DW Huang J Tulpule A and Levine AM Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group N Engl J Med 336 1997 1641-1648
13. Rossi G Donisi A Casari S Re A Cadeo G and Carosi G The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma Cancer 86 1999 2391-2397
14. Navarro JT Ribera JM Oriol A Vaquero M Romeu J Battle M Flores A Milla F and Feliu E Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone Br J Haematol 112 2001 909-915